9
Clinical Trials associated with Trastuzumab biosimilar(Genor Biopharma Co., Ltd.)单中心、随机、盲法、平行对照评价GB221和赫赛汀在中国健康成年志愿者中单次给药的药代动力学比对研究
[Translation] A single-center, randomized, blinded, parallel controlled pharmacokinetic comparison study of GB221 and Herceptin in healthy adult volunteers after single administration
通过药代动力学试验,评价单次给药后注射用重组抗HER2人源化单克隆抗体GB221和赫赛汀的主要药代动力学参数Cmax、AUC(0- t),AUC(0-∞)的相似性。
[Translation] Pharmacokinetic studies were performed to evaluate the similarity of the main pharmacokinetic parameters Cmax, AUC(0-t), and AUC(0-∞) between the recombinant anti-HER2 humanized monoclonal antibody GB221 for injection and Herceptin after a single dose.
A Single Center, Randomized, Blind, Parallel Controlled, Single Dose Pharmacokinetic Study of Recombinant Humanized Anti-HER-2 Monoclonal Antibody Injection GB221 in Comparison With Herceptin ® in Chinese Healthy Adult Volunteers
This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and Herceptin ®.
比较GB221联合多西他赛和曲妥珠单抗联合多西他赛一线治疗HER2阳性的转移性乳腺癌患者的有效性、安全性的III期临床试验
[Translation] A phase III clinical trial comparing the efficacy and safety of GB221 combined with docetaxel and trastuzumab combined with docetaxel as first-line treatment for patients with HER2-positive metastatic breast cancer
比较GB221 联合多西他赛与曲妥珠单抗联合多西他赛两组的18 周客观缓解率(ORR)。
[Translation] The 18-week objective response rate (ORR) of GB221 combined with docetaxel and trastuzumab combined with docetaxel was compared.
100 Clinical Results associated with Trastuzumab biosimilar(Genor Biopharma Co., Ltd.)
100 Translational Medicine associated with Trastuzumab biosimilar(Genor Biopharma Co., Ltd.)
100 Patents (Medical) associated with Trastuzumab biosimilar(Genor Biopharma Co., Ltd.)
100 Deals associated with Trastuzumab biosimilar(Genor Biopharma Co., Ltd.)